top of page
Pipeline Overview
Nanodose Therapeutics is committed to advancing its nanodosed recombinant proteins to develop life-enhancing medicines for people suffering from chronic debilitating conditions.
Our pipeline is focused in four areas:
-
Chronic Traumatic Brain Injury
-
Alzheimer's Disease
-
Stroke
-
hypermobile Ehlers-Danlos Syndrome
Candidate
Description
Target Indication
Lead
Generation
Lead Optimization
IND
Enabling
IND
Phase I
Phase II
Phase III
IND Submission planned for August 2024
bottom of page